Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Benzinga's Top Ratings Upgrades, Downgrades For October 3, 2022

Upgrades

For Sensei Biotherapeutics Inc (NASDAQ:SNSE), Oppenheimer upgraded the previous rating of Perform to Outperform. For the second quarter, Sensei Biotherapeutics had an EPS of $0.34, compared to year-ago quarter EPS of $0.32. The current stock performance of Sensei Biotherapeutics shows a 52-week-high of $6.17 and a 52-week-low of $1.45. Moreover, at the end of the last trading period, the closing price was at $1.55.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.